China has a better general industrial infrastructure than India because the Chinese government has put enormous efforts and investments in this during the past two decades. The logistic service in China also is better developed and less expensive than in India. These advantages have made China attractive to foreign companies looking for a country where doing business is relatively easy. Thus a framework of the Industrial structure need to be improved by Indian Government.- China has a better education system in biology, molecular biology, and other life science–related fields, resulting in, generally speaking, a better biotech industry in China than in India. However, India has paid attention to promoting its pharmaceutical industry a lot earlier than China but need more emphasis on the same to get qualified professionals for industry.
- The current labour and raw material costs in the Indian pharmaceutical industry are generally about 25% to 30% higher than in China. Indian to pharma companies should pay attention towards long-term, large-scale manufacturing projects to source bulk materials or outsource.
- India’s current strengths include its stronger capability in process development, drug formulation, dosage form manufacturing, and marketing in well regulated markets. India should strengthens for its better industrial support system, large-scale manufacturing capabilities of raw materials, and relatively low labour and material costs.
- At present, the Indian companies are the better choice for formulation development, manufacturing, and marketing of dosage form drugs. and India should concentrate more on contract manufacturing (and sourcing) of advanced pharma intermediates and APIs..
Thus it is to conclude that in my opinion Indian Manufacturing and sourcing companies of Active Pharmaceutical Ingredients and Intermediates should participate in CPhI China in June 2017 for getting more opportunities and learning experiences from Chinese counter parts.
Created By: Vinita Bhandari www.getdigitalpartner.com
